
    
      Each participant received a total of two, approximately 12-hour continuous infusions of
      ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between
      treatments.

      This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.
    
  